Year in Review 2024 - NSCLC Perioperative Therapy

Oncology 2024 Year in Review

B. Halmos

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

ESMO 2024 Summary: Management of Oligoprogressive Disease - Patients…

2024 ESMO Annual Meeting Insights Hub

R. Van den Begin

Adjuvant & Neoadjuvant Therapy in Early NSCLC With Actionable Genomi…

Fox Chase Cancer Center

J. Reuss

Year in Review 2024 - Top Clinical Trials in Neuro-Oncology

Oncology 2024 Year in Review

S. Bagley

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

IO Advances in Metastatic NSCLC Treatment

Fox Chase Cancer Center

H. Borghaei

An Update on Lung Cancer Targeted Therapies: The Evolution of Person…

University of Miami Sylvester Comprehensive Cancer Center

E. Rodriguez

ASCO® 2024 Lung Cancer Highlights: CROWN, LAURA, ADRIATIC, and PALOM…

2024 ASCO® Annual Meeting Insights Hub

L. Raez

New Frontiers in Oncology: Advanced Diagnostics and Therapeutics

Springer Healthcare IME

S. Peters

Options for Osimertinib-Resistant NSCLC

MI&T Congressi

T. Bivona

Biomarker Testing in aNSCLC: Current Guidelines, Gaps, and Impact on…

UChicago Medicine

R. Thawani

Treatment Strategies for Metastatic HER2-Mutant NSCLC

UNC Lineberger Comprehensive Cancer Center

S. Patel

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

ecancer

E. Felip, A. Spira, A. Passaro, A. Addeo

Biomarker Testing in NSCLC

Martin Dietrich

Prognosis and Outcomes for BRAF-Mutated NSCLC

Filippo de Marinis

Key Metastatic NSCLC Trial Updates Including MARIPOSA and FLAURA2

Yale Cancer Center

S. Goldberg

Management of mNSCLC Without Actionable Mutations

Integrity CE

M. Baumgart, S. Liu

Clinical Implications of Tumor Agnostic Therapies

Shivaani Kummar